drugset / Trial / NCT00615615

Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures

NCT00615615

Phase 3 Completed 216 enrolled UCB Pharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Double-blind, randomized, placebo-controlled, multi-center clinical trial conducted to evaluate levetiracetam as adjunctive therapy in children (4-16 years) with refractory partial onset seizures.

Timeline

Start
1999-09
Primary completion
2003-03
Completion
2003-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 60 mg/kg

Indications